Evidence Based Treatment of Vestibular Migraine 2020
Michael Teixido MD
Revised 1/2020

This simple summary with supporting links is intended to make proven treatment options available to clinicians who treat Vestibular Migraine. Most vestibular migraine treatment mirrors treatment of chronic migraine headache. Listed here are the agents with usefulness in Vestibular Migraine documented in published studies. Some useful medications are listed that are helpful and proven in migraine headache treatment but await published studies regarding effectiveness for vertigo prevention in VM.

Diet/Caffeine Cessation

16% response at 6 weeks

Abortive Medications

1. Almotriptan (Axert) 12.5mg 18pts, 55% complete, 28% had 50% reduction

2. Sumatriptan (Imitrex) 53pts Efficacy for HA4, for vertigo 3(1-4)

3. Prednisone 50mg/d- no studies
4. Promethazine 25mg- no studies

Abortive Neuromodulation Treatments(devices)

Cefaly device- 19/19 patients reported improvement in vertigo severity with 20m eTNS. 61% improvement in vertigo/ 77%improvement in headache.

Non-invasive vagus nerve stimulation- 18 pts. 47% reduction in vertigo severity/ 63% reduction in headache
Shin C. Beh, Deborah I. Friedman Acute vestibular migraine treatment with noninvasive vagus nerve stimulation Neurology Oct 2019, 93 (18) e1715-e1719

Preventive Medications

1. Amitriptyline 25-50mg daily, Significant improvement in 77% taking 25 mg daily, 100% taking 50 mg daily

2. Nortriptyline 25-75mg daily: 46% response
3. Propranolol 40 mg daily titrating up to a maximum of 160 mg,-vertigo decreased 12.6/mo to 1.9 -severity 7.3 decreased to 2.1
   
   
   Propranolol (average dose 80 mg), 73% improvement
   
   
   Propranolol 38 pts. 40-60mg b.i.d. DHI before and after treatment were 50.21±22.39 (range: 8-92) and 9.31±9.86 (range: 0-58)
   
   
   Metoprolol 95mg/d  130 pts Randomized Placebo Controlled Study- No benefit over placebo
   

4. Topiramate 25 or 50 mg twice daily, vertigo attacks decreased from 5.5 to 1/mo, severity dec by 75%
headache decreased from 4 to 1/mo, severity decreased by 50%
   
   
   Topiramate 25-50mg BID 25% response
   
   
   Topiramate 50mg BID- improved tinnitus, mild HL in 10/10 VM pts
   

5. Venlafaxine 37.5 mg daily titrated up to a maximum of 150 mg
   
   -vertigo decreased 12.2 to 2.6/mo, severity decreased 7.9 to 1.8
   
   
   6. Acetazolamide 250mg BID, vertigo decreased 3.9 to 1.4/mo, headache decreased 4.31 to 2.85.
   

7. Lamotrigine 100 mg daily, (Na+ blocker, mood stabilizer) vertigo decreased 18.1 to 5.4/mo.
   
   26% complete response
   
   Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study.

8. Cinnarizine (not available in USA)(Ca++ channel blocker) 37.5 mg for 3 days then increased to 75 mg
   
   HA frequency decreased 3.9 to 0.75/mo, duration dec 24 to 3 h, intensity dec 8 to 1/10
   
   Vertigo decreased from 3.8 to 0.4/mo
   
   
   Cinnarizine effective and tolerated in adolescents-20 subjects 15-19. VAS dizziness improved from 7.2-2.6 and headache frequency dropped from 20d/mo to 5.75.
   
   Choi Yun-Ju; Lee Seung-Han Effect of Cinnarizine For the Prophylaxis of Vestibular Migraine In Adolescents (abstract)

9.Flunarizine (not available in USA)(Ca++ channel blocker) 10 mg + betahistine 16 mg tid, 64%
decreased vertigo, 61% decreased vertigo severity
No change in headache

Flunarizine 10 mg, 68% reported improvement in vestibular symptoms

Flunarizine 10 mg, 9/10 sig improvement

10. Diltiazem(Ca++ channel blocker) 120mg daily- no studies
11. Verapamil – modest reductions in HA and vertigo frequency and severity in 11 of 17 pts with MV and MD on very low dose verapamil(40mg bid)


Vestibular Rehabilitation

Mixed results in 6 studies: tendency to improvement. None with controls. Many patients had other diagnoses, Many patients cannot tolerate PT- “Dose” of therapy is important. May help if concurrent BPPV, unilateral weakness.


Rationale for use of agents for treatment of VM and needed areas of study

There are still no placebo controlled studies in this area.

GABA enhancers γ-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain. Loss of GABA inhibition has been clearly implicated in epileptogenesis but may also play a role in VM as GABAergic projections from the cerebellum to the vestibular nuclei inhibit activity.

- Benzodiazepines are GABA modulators, act centrally to suppress vestibular responses. Gain is decreased and time constant increased.
- Gabapentin, cyclic analogue of GABA, enhances GABA synthesis and decreases neuronal calcium influx via a specific subunit of voltage-dependent calcium channels.
- Topiramate acts, via an action on a novel site of the GABA\textsubscript{A} receptor. It is also a sodium channel blocker.
- Tiagabine elevates synaptic GABA levels by inhibiting the GABA uptake transporter, GAT1, and preventing the uptake of GABA into neurons and glia. NO data in VM
- 4-Aminopyridine. Aminopyridines augment GABA release by cerebellar Purkinje cells by a primary action on potassium channels. Useful for many cerebellar disorders and well tolerated. NO data in VM.
- Acetazolamide, augments GABAergic neuronal activity, may change the excitability of neurons by a pH shift towards acidification.
- Valproic acid, increases brain GABA levels and may suppress migraine-related events in the cortex, perivascular parasympathetics or trigeminal nucleus caudalis.

**CGRP ligand/receptor binders** Calcitonin gene-related peptide (CGRP) receptor blockers. CGRP plays an important role in cerebral autoregulation. In migraine CGRP activates vanilloid receptors and is responsible for vasoactive inflammatory neuropeptide release from unmyelinated c-fibers. Migraine-related sensitization of the trigeminal nuclei affects the sensitivity of structures that receive trigeminal nuclear projections. Blocking CGRP may decrease activity of projections to the vestibular nuclei and prevent vestibular sensitization in migraine patients. 2 classes:

  - **Monoclonal antibodies** Do not enter cells or cross BBB
    - erenumab NO data
    - fremanezumab NO data
    - galcanezumab NO data
  - **Small molecules** May enter cells and cross BBB
    - Release for clinical use expected 2020-21

**Beta-Blockers** While beta blockers block sympathetic/adrenergic-induced vasoconstriction their beneficial effects in migraine headache prophylaxis are unclear. Studies show stabilization of the CNS with restoration of habituation to light stimuli at the occipital cortex. Exact mechanisms and sites of activity are unknown. They can be quick acting in migraine as evidenced by reports of timolol eye drop effectively aborting migraine headache. Long used in migraine headache prophylaxis, and used to treat VM there is one RCT documenting efficacy in VM.

**Calcium Channel Blockers** Voltage-dependent Ca2+ channels are integral membrane proteins that permit extracellular Ca2+ to enter cells down their electrical and concentration gradients and have a universal role in stimulus-response coupling in excitable cells. Calcium channel blockers reduce channel opening in response to membrane depolarization in neurons thereby stabilizing neural tissues and can also decrease vasoconstriction by decreasing calcium influx into muscle cells. There is ample evidence supporting the use of Ca2+ blocking agents in migraine headache prophylaxis.

**Anticonvulsants** The mechanisms of these drugs in migraine are not well understood. It is thought that anticonvulsants act on voltage- and receptor-gated sodium ion channels promoting stabilization of neuronal membranes and preventing repetitive firing. They are thereby able to block excitation leading to cortical spreading depression that may be a central precipitator in migraine. These agents have variable GABA enhancing effects as well.

**Tricyclic Antidepressants** Long used in migraine headache these have many potentially beneficial effects. They are medium potency sodium and calcium channel blockers so stabilize membranes and can prevent cortical depression, are anticholinergic so suppress vestibular function and dysautonomia associated with increased parasympathetic outflow common in migraine, and are serotonin and norepinephrine reuptake inhibitors. Varying populations of serotonin receptors are found in the trigeminal nucleus, vestibular nuclei, inner ear and in serotonergic pathways from the dorsal raphe nucleus to the vestibular nuclei.